A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Confirmed diagnosis of rheumatoid arthritis
Meets Class I, II or III of the ACR 1991 Revised Criteria
RA seropositivity
Stable dose of methotrexate
Inadequate response to TNF inhibitors
You may not be if
Any prior treatment with lymphocyte depleting therapies
History of active TB infection
Known or screen test positive for specific viruses or indicators of viral infection
Clareo Health | A Pharmacokinetic/Pharmacodynamic Study Comparing PF-05280586 To Rituximab In Subjects With Active Rheumatoid Arthritis With An Inadequate Response To TNF Inhibitors (REFLECTIONS B328-01)
